What is the recommended dosing, contraindications, and major adverse effects of mirabegron for treating overactive bladder?

Mirabegron for Overactive Bladder

Mirabegron should be offered as a first-line pharmacotherapy option for overactive bladder at a dose of 50 mg once daily, and is particularly preferred over antimuscarinic medications due to its superior safety profile, especially regarding cognitive risks and dry mouth. 1

Recommended Dosing

Standard dosing is 50 mg once daily, taken with water and swallowed whole (do not crush, chew, or break). 2 Adults may take it with or without food, though children should take it with food. 2

• Starting dose: 25 mg once daily may be used in older patients with multiple comorbidities 3, but 50 mg is the optimal therapeutic dose for long-term efficacy 4
• Maximum dose: 50 mg once daily (the 100 mg dose showed similar efficacy without additional benefit) 4
• Dose adjustments: Required for severe renal impairment (CrCl 15-29 mL/min) or moderate hepatic impairment—maximum 25 mg daily 2

The evidence strongly supports that 50 mg once daily maximizes clinical benefit with improvements evident as early as week 4 and maintained throughout long-term treatment. 4, 5

Contraindications and Precautions

Absolute Contraindications

• Severe uncontrolled hypertension 2
• Patients with severe hepatic impairment (Child-Pugh Class C)
• End-stage renal disease (CrCl <15 mL/min) 2

Relative Contraindications and Cautions

• Bladder outlet obstruction or urinary retention: Use with extreme caution as mirabegron may worsen urinary retention, particularly when combined with other OAB medications 2
• Narrow-angle glaucoma: While this is a primary concern with antimuscarinics, mirabegron's mechanism avoids this issue, making it preferable in these patients 1
• Controlled hypertension: Can be used but requires blood pressure monitoring; approximately 6.5% of patients may experience blood pressure increases requiring discontinuation 6

Drug Interactions

Mirabegron is a moderate CYP2D6 inhibitor. Exercise caution with:

• Thioridazine
• Flecainide
• Propafenone
• Digoxin 2

Major Adverse Effects

Common Adverse Effects (Adults with OAB)

• Hypertension (most significant concern—monitor blood pressure regularly) 2
• Nasopharyngitis (most common overall; OR 1.54 vs placebo) 7
• Urinary tract infection
• Headache 2

Common Adverse Effects (Children with Neurogenic Detrusor Overactivity)

• Urinary tract infection
• Nasopharyngitis
• Constipation
• Headache 2

Serious Adverse Effects

• Increased blood pressure: Requires monitoring throughout treatment; may worsen pre-existing hypertension 2
• Urinary retention: Particularly in patients with bladder outlet obstruction 2
• Angioedema: Rare but serious—requires immediate discontinuation and emergency care if swelling of lips, face, tongue, or throat occurs 2

Cardiovascular Safety

Large integrated database analysis demonstrated acceptable cardiovascular safety profile 3, though hypertension remains the primary cardiovascular concern requiring monitoring. 2

Clinical Advantages Over Antimuscarinics

The key clinical advantage is the dramatically lower incidence of dry mouth—similar to placebo and 3-5 fold less than tolterodine ER 4 mg. 5 This is critical because dry mouth is the most common reason for antimuscarinic discontinuation.

Critically, mirabegron avoids the cognitive risks associated with antimuscarinics. The 2024 AUA/SUFU guidelines emphasize that antimuscarinic medications are associated with increased risk of dementia and cognitive impairment in a cumulative, dose-dependent manner, and recommend that beta-3 agonists are typically preferred before antimuscarinics. 1

Efficacy Profile

Meta-analysis of nine Phase II/III trials (n=8,527) demonstrated:

• Volume voided per micturition: +13 ml increase 4
• Micturition frequency: 5 fewer episodes per week 4
• Incontinence episodes: 4 fewer per week 4
• Onset of action: Significant improvements by week 4, maintained long-term 5

When compared to tolterodine 4 mg, mirabegron 50 mg showed significant reduction in micturition frequency (MD -0.16) and overall adverse events (OR 0.71). 8

Combination Therapy

Mirabegron can be combined with solifenacin for refractory cases, providing additive benefits without proportionally increased adverse effects. 3 The 2024 AUA/SUFU guidelines support combining therapies when monotherapy is inadequate, though additions should be made stepwise to assess individual impact. 1

Monitoring Requirements

• Blood pressure: Check at baseline and monitor regularly during treatment 2
• Post-void residual: Assess in patients at risk for urinary retention 2
• Symptom response: Evaluate by 4 weeks; if no improvement, consider alternative therapy 1

Common Pitfalls to Avoid

1. Do not use in severe uncontrolled hypertension—this is an absolute contraindication 2
2. Do not combine with multiple OAB medications initially without assessing bladder emptying, especially in men with possible outlet obstruction 2
3. Do not assume all beta-3 agonists are equivalent—this evidence is specific to mirabegron 4
4. Do not forget to counsel about blood pressure monitoring—home monitoring can detect early increases 6
5. Do not start at 25 mg in most patients—50 mg is the optimal dose for efficacy 4